Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) FCF Margin (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed FCF Margin for 15 consecutive years, with 353.17% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin changed N/A to 353.17% in Q3 2025 year-over-year; TTM through Sep 2025 was 195.09%, a 10328.0% decrease, with the full-year FY2024 number at 53.05%, down 1211.0% from a year prior.
  • FCF Margin was 353.17% for Q3 2025 at NovaBay Pharmaceuticals, down from 27.46% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 27.46% in Q4 2024 to a low of 353.17% in Q3 2025.
  • A 5-year average of 73.93% and a median of 55.96% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -6712bps in 2021, then surged 6460bps in 2022.
  • NovaBay Pharmaceuticals' FCF Margin stood at 97.78% in 2021, then soared by 66bps to 33.19% in 2022, then decreased by -4bps to 34.51% in 2023, then surged by 180bps to 27.46% in 2024, then tumbled by -1386bps to 353.17% in 2025.
  • Per Business Quant, the three most recent readings for NBY's FCF Margin are 353.17% (Q3 2025), 27.46% (Q4 2024), and 43.33% (Q2 2024).